Drug launches don’t succeed at the finish line. They succeed or fail years earlier, when teams decide what evidence they’ll generate, how they’ll publish it, and which assumptions they’ll pressure-test before it’s too late. In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Ana Bozas, Director of Clinical Evidence Strategy and Scientific Communications at Vera Therapeutics, to dive into what launch readiness really means from the medical side.

Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.

The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.

Pharma Sessions is hosted by Jonathan Kaskey

Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

Or join the Pharma Sessions Substack:
www.pharmasessions.substack.com